| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15929894 | IVTH | 0.02 - 0.8 % | 0.2 - 0.8 % | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:27916585 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Alters hypothalamic-pituitary-thyroid axis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Alters hypothalamic-pituitary-thyroid axis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| PMID:28962449 | IVR | 10 mg/kg/day | 10 mg/kg/day | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 250 mg/kg/day | 250 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Induce apoptosis in adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.